PCSK9 and triple-A syndrome: Notably, in spite of controlling for statin use, individuals with genetic PCSK9 LoF had further reduction in risk from both CAD and AAA, arguing for an additional benefit of PCSK9 inhibition in modifying risk of atherosclerotic vascular disease in individuals with suboptimal lipid control who are already taking a statin.